Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON TrialOnce-Nightly Sodium Oxybate Early EfficacyL. Krahn et al.

被引：1

作者：

Lois Krahn ^{[1
]}

Asim Roy ^{[2
]}

John W. Winkelman ^{[3
]}

Anne Marie Morse ^{[4
]}

Jennifer Gudeman ^{[5
]}

机构：

[1] Mayo Clinic,Geisinger Commonwealth School of Medicine, Geisinger Medical Center

[2] Ohio Sleep Medicine Institute,Medical and Clinical Affairs

[3] Massachusetts General Hospital,undefined

[4] Janet Weis Children’s Hospital,undefined

[5] Avadel Pharmaceuticals,undefined

来源：

CNS Drugs | 2025年 / 39卷 / Suppl 1期

关键词：

D O I：

10.1007/s40263-024-01143-7

中图分类号：

学科分类号：

摘要：

引用

页码：53 / 59

页数：6

共 35 条

[21] EFFICACY OF ONCE-NIGHTLY SODIUM OXYBATE (ON-SXB; FT218) FOR EXCESSIVE DAYTIME SLEEPINESS AND CATAPLEXY: POST-HOC NUMBER NEEDED TO TREAT AND EFFECT SIZE ANALYSES FROM REST-ON
Thorpy, M.
Roth, T.
Kushida, C.
Seiden, D.
Dubow, J.
Gudeman, J.
SLEEP MEDICINE, 2022, 100 : S157 - S158
[22] IMPROVEMENT IN SLEEP LATENCY WITH FT218 (ONCE-NIGHTLY SODIUM OXYBATE): ANALYSIS FROM THE PHASE 3 REST-ON CLINICAL TRIAL
Thorpy, Michael
Shapiro, Colin
Kushida, Clete
Ohayon, Maurice
Dubow, Jordan
Gudeman, Jennifer
SLEEP, 2023, 46
[23] CATAPLEXY RESPONSE WITH FT218, A ONCE-NIGHTLY SODIUM OXYBATE: POST-HOC RESPONDER ANALYSES FROM THE PHASE 3 REST-ON CLINICAL TRIAL
Corser, Bruce
Ajayi, Akinyemi
Thorpy, Michael
Seiden, David
Dubow, Jordan
Bogan, Richard
CHEST, 2021, 160 (04) : 2412A - 2414A
[24] CHARACTERIZATION OF PATIENTS WHO HAD ≥5% WEIGHT LOSS WITH FT218 (ONCE-NIGHTLY SODIUM OXYBATE): POST HOC ANALYSIS FROM REST-ON
Roth, Thomas
Morse, Anne
Bogan, Richard
Roy, Asim
Dubow, Jordan
Gudeman, Jennifer
Dauvilliers, Yves
SLEEP, 2023, 46
[25] Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial
Dauvilliers, Yves
Roth, Thomas
Bogan, Richard
Thorpy, Michael J.
Morse, Anne Marie
Roy, Asim
Gudeman, Jennifer
SLEEP MEDICINE, 2024, 124 : 209 - 216
[26] SLEEP LATENCY RESPONSE WITH FT218, A ONCE-NIGHTLY SODIUM OXYBATE: POST-HOC RESPONDER ANALYSES FROM THE PHASE 3 REST-ON CLINICAL TRIAL
Winkelman, John
Ohayon, Maurice
Thorpy, Michael
Seiden, David
Bogan, Richard
Dubow, Jordan
Shapiro, Colin
CHEST, 2021, 160 (04) : 2426A - 2428A
[27] Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
Roth, Thomas
Dauvilliers, Yves
Thorpy, Michael J.
Kushida, Clete
Corser, Bruce C.
Bogan, Richard
Rosenberg, Russell
Dubow, Jordan
Seiden, David
CNS DRUGS, 2022, 36 (04) : 377 - 387
[28] Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
Thomas Roth
Yves Dauvilliers
Michael J. Thorpy
Clete Kushida
Bruce C. Corser
Richard Bogan
Russell Rosenberg
Jordan Dubow
David Seiden
CNS Drugs, 2022, 36 : 377 - 387
[29] Polysomnographic Measures of Sleep Continuity in Patients With Narcolepsy: Results From the REST-ON Trial, a Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation
Dauvilliers, Yves
Thorpy, Michael
Roth, Thomas
Rosenberg, Russell
Corser, Bruce
Shapiro, Colin
Ajayi, Akinyemi
Dubow, Jordan
Seiden, David
Kushida, Clete
NEUROLOGY, 2021, 96 (15)
[30] CATAPLEXY RESPONSE WITH ONCE-NIGHTLY SODIUM OXYBATE: POST HOC RESPONDER ANALYSIS FROM THE PHASE 3 REST-ON CLINICAL TRIAL
Thorpy, M. J.
Kushida, C. A.
Ajayi, A. O.
Dubow, J.
Gudeman, J.
SLEEP MEDICINE, 2024, 115 : 208 - 209

← 1 2 3 4 →